Marc S. Raab
@RaabMarc
Followers
358
Following
149
Statuses
118
Clinician and scientist focusing on multiple myeloma. Tweets are my own. @HDMyeloma @ukhd @dkfz
Heidelberg, Deutschland
Joined April 2023
So proud of our team @HDMyeloma !
Our new work is now published in @SciImmunology and made it to the cover! 🚀 Led by Niels Weinhold & Simon Haas @haas_lab Outside the bone marrow, myeloma cells battle immune cells within distinct immune islands 🔬 Read here
0
3
24
Attend on-site or virtually! Confirmed speakers include @IdoAmitLab @NBahlis @FrancescoMaura4 @BrunoPaiva_UNAV @szusmani @myelomaMD @MyMKaiser @SagarLonialMD @TCupedo @Leif_Bergsagel @DrGarethMorgan1 @MarkBustoros and many more!!
📣 We are excited to announce the 10th Heidelberg Myeloma Workshop Join us on April 25–26, 2025, as international & local experts share the latest advancements in multiple myeloma research. #mmsm ✅ CME-certified 🔗 Speaker line-up & registration 👇🏼
3
9
25
RT @HDMyeloma: 📣 We are excited to announce the 10th Heidelberg Myeloma Workshop Join us on April 25–26, 2025, as international & local e…
0
12
0
@FrancescoMaura4 @MSKCancerCenter @szusmani @SohrabShah @MSK_DeptOfMed @CompOncMSK Happy to continue the collaboration beyond what is already in the pipeline 🎉
1
0
1
RT @VJHemOnc: Wrapping up day 1 at the Oxford Myeloma Workshop with a joint interview w/ @RascheLeo and Neils Weinhold, who discussed their…
0
3
0
Thanks, Bob, for highlighting. Great work by the great team from #GMMG and all investigators! @HDMyeloma @marc_a_baertsch, @EliasKarlMai and all authors
#Myeloma Paper of the Day: Long-term follow-up of Phase 3 GMMG ReLApsE trial of second ASCT finds median PFS was 20.5 & 19.3 months in transplant & control arms; median OS 67.1 and 62.7 months: #mmsm Overall, does not support routine use of salvage ASCT.
4
1
10
RT @NicoGagelmann: 🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis @NEJM
0
53
0
RT @BloodJournal: sBCMA, surface antigen density, effector-to-target ratio, and TCE dose collectively mediate primary refractoriness to ant…
0
10
0
RT @FrancescoMaura4: Just before the holidays, new preprint from the lab on @biorxivpreprint! Super talented @BenDiamondMD reports CD38 los…
0
22
0
1
0
1
Let me introduce 📣 ‘Team MRD💯‘ in TE-NDMM #ASH24 #GMMG #DSMM @EMN_EuMMnet
@RascheLeo @ElenaZamagni NvdDonk @HDMyeloma
0
6
25
RT @ForsbergMD: This is the start of a revolution. Still lots of work to do but the future of myeloma therapy is clear to see and it couldn…
0
4
0
RT @HealthTree: Early but promsing data just presented by @RaabMarc at #ASH24 on using bispecific antibodies in first line! A 100% of patie…
0
9
0
RT @RahulBanerjeeMD: #ASH24 @RaabMarc presenting MajesTEC-5 (frontline bsAb) now! Obviously will talk about efficacy next, but 👏 look 👏 a…
0
14
0
RT @RahulBanerjeeMD: #ASH24 just for context - in DETERMINATION published just a few years ago, MRD neg (10^-5) AFTER ASCT was ~54%. In Ma…
0
8
0
RT @HadidiSamer: #ASH24 #mmsm @ASH_hematology Myeloma oral: GMMG-HD7 Trial @EliasKarlMai This is important study Isa-VRD induction res…
0
12
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Myeloma long-term survivors exhibit sustained immune alterations decades after 1st-line tx even…
0
16
0
Indeed a very important finding from a great collaboration between @HDMyeloma and @haas_lab
Oof :( The bone marrow TME can remain inflamed (so to speak) for years after achieving a CR in myeloma... Unclear how clinically relevant this is in terms of infection risk / predisposing to relapses, but fascinating. (Thanks @MyelomaAmateur for finding this article!)
1
4
18